RxDoctor Payments Data

Erik Dingley

Optometrist · North Smithfield, RINPI 1255614392

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 30.7% of the total. 2025 is the largest year on record at $561, 8.7 times the $65 reported in 2019.

$1,824in general payments, 2019–2025

Across 108 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$560
  • Alcon$508
  • Oyster Point Pharma, Inc.$263
  • Tarsus Pharmaceuticals, Inc.$167
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$104
  • Dompe US, Inc.$69
  • plus $154 from 6 others

What the payments were for

  • Food & beverage$1,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,824 in reported general payments places this provider in the 80th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$50,849
Medicare patients
235
Services billed
1,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost53$24,115
TyrvayaVarenicline Tartrate13$12,934
RestasisCyclosporine12$11,363
Latanoprost220$3,172
Timolol Maleate78$1,192
Dorzolamide Hcl47$1,063
Prednisolone Acetate20$1,040
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha56$627
Brimonidine Tartrate45$521
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$452
Cephalexin15$225
Doxycycline Hyclate13$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$560$35,47865 claims
Oyster Point Pharma, Inc.Tyrvaya$263$12,93413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in North Smithfield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →